Literature DB >> 4027124

Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.

C Nordin, B Siwers, J Benitez, L Bertilsson.   

Abstract

In 20 depressed patients treated with nortriptyline (NT) there was a significant relationship between the plasma concentration of NT and the debrisoquine metabolic ratio (rs = 0.77; P less than 0.01). (The debrisoquine test was performed after stopping NT treatment). This is in agreement with the hypothesis that the hydroxylations of NT and debrisoquine are mediated by similar enzymatic mechanisms. In contrast there was no significant relationship between the debrisoquine metabolic ratio and the plasma concentrations of the active metabolite 10-hydroxy-nortriptyline. In 11 of the patients the debrisoquine metabolic ratio was significantly higher during than after NT treatment. This may be due to an inhibition of the debrisoquine hydroxylation by NT.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027124      PMCID: PMC1463875          DOI: 10.1111/j.1365-2125.1985.tb02723.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  A gas chromatographic method for the quantitative determination of notriptyline and some of its metabolites in human plasma and urine.

Authors:  O Borgå; M Garle
Journal:  J Chromatogr       Date:  1972-05-31

2.  Pronounced inhibition of noradrenaline uptake by 10-hydroxymetabolites of nortriptyline.

Authors:  L Bertilsson; B Mellström; F Sjöqvist
Journal:  Life Sci       Date:  1979-10-08       Impact factor: 5.037

3.  Genetically determined oxidation capacity and the disposition of debrisoquine.

Authors:  T P Sloan; R Lancaster; R R Shah; J R Idle; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

4.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

Authors:  L Bertilsson; A Aberg-Wistedt
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

5.  Accumulation of debrisoquine by platelets in vivo: a model of events at the peripheral adrenergic neurone.

Authors:  J H Silas; G T Tucker; A J Smith; N R Fieller
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

6.  Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.

Authors:  N M Woolhouse; K K Adjepon-Yamoah; B Mellström; A Hedman; L Bertilsson; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

7.  E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors:  B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

8.  Correlation between nortriptyline and debrisoquine hydroxylation in the human liver.

Authors:  C von Bahr; C Birgersson; A Blanck; M Göransson; B Mellström; K Nilsell
Journal:  Life Sci       Date:  1983-08-15       Impact factor: 5.037

9.  Weak binding of 10-hydroxymetabolites of nortriptyline to rat brain muscarinic acetylcholine receptors.

Authors:  A Wägner; B Ekqvist; L Bertilsson; F Sjöqvist
Journal:  Life Sci       Date:  1984-09-24       Impact factor: 5.037

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  19 in total

Review 1.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

2.  Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.

Authors:  E Spina; C Gitto; A Avenoso; G M Campo; A P Caputi; E Perucca
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

3.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Debrisoquine oxidation phenotype during neuroleptic monotherapy.

Authors:  E Spina; C Martines; A P Caputi; J Cobaleda; B Piñas; J A Carrillo; J Benitez
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.

Authors:  Jónrit Halling; Pál Weihe; Kim Brosen
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

Review 7.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

8.  Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.

Authors:  K Brøsen; R Klysner; L F Gram; S V Otton; P Bech; L Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxy-nortriptyline.

Authors:  C Nordin; L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 10.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.